WORKING TOGETHER

Profiles of Collaboration
Alzheimer’s disease (AD) is a tragic loss-of-mind illness that affects 1 of every 4 people over age 75, and their caregivers. It also takes an enormous toll on society. At over $100 billion per year, AD is the third most costly disease in the U.S. after heart disease and cancer. Currently, 18 million cases have been reported worldwide. In the coming years, with baby boomers aging, the number of cases will triple. The devastating personal and societal costs of AD can be reduced by developing new drugs. With just 4 modestly effective drugs on the market today that only treat the symptoms of the disease but not the cause, it is imperative that our research efforts be accelerated.
While basic research generally funded by foundations and government seeks to find the causes of AD, new treatments come from drug discovery research, where chemical compounds that will be used for pills are created. Developing effective AD drugs will enable older persons to die with dignity and save billions in healthcare costs. This is an achievable goal. The Institute for the Study of Aging (ISOA), an Estée Lauder family foundation founded in 1998, and the Alzheimer’s Drug Discovery Foundation (ADDF), an affiliated public charity established in 2004, are committed to funding the development of new treatments for AD through venture philanthropy.
Neurotrophins are naturally occurring proteins that can prevent and treat neuronal degeneration. These proteins are too large to be taken orally or to adequately penetrate the central nervous system to be useful as drugs. The development of small compounds that mimic the key parts of neurotrophins has been a much sought after goal. Support from the Institute for the Study of Aging (ISOA) allowed us to launch a high risk program in which we applied advanced drug modeling to develop the first drug-like small molecules capable of preventing neural degeneration.
Given the high risk, but potentially high yield, approach of our research, it was quite difficult to obtain funding. The ISOA has created an exceptional vehicle for funding where risks and benefits of innovative drug discovery programs are explored in depth and in the context of translational research that is very different from traditional foundations. In addition to their financial support, ISOA provides expert technical assistance that is unparalleled to any other philanthropic organization. With their help, my lab is now testing our drug-like molecules in mice with AD.
Beta-secretase has long been recognized as a main therapeutic target for the development of drugs to treat AD. When my laboratory cloned beta-secretase and determined its basic properties, the stage was set for actual drug development. We recognized that such development would require organization and funding. Together with Arun Ghosh, we founded a biotechnology company named Zapaq, with the mission to develop beta-secretase inhibitor drugs. One of two initial sources of seed funding came from the ISOA.
Their funding was critical for Zapaq because it allowed us to obtain business and legal assistance in setting up the framework of the company. It also helped us to recruit key scientists and begin our research program, as well as seek follow-on funding. Today, at three-years-old, Zapaq has stable financing from venture capital companies. Its research team has used structure-based design to attain advanced drug candidates. Such programs afford optimism that a drug candidate will be tested in human clinical trials in the near future. Without ISOA’s assistance, it would have been difficult for our company to come into existence.
Elan Pharmaceuticals is proud to be working with the Alzheimer’s Drug Discovery Foundation (ADDF), an ISOA affiliated public charity, to support innovative drug discovery for AD. The program that we collaboratively launched in 2005, *Novel Approaches to Drug Discovery for Alzheimer’s Disease*, seeks to identify and fund promising research in academic and biotech labs around the world. Alliances such as these, among biotechnology companies, philanthropies and academic institutions, are crucial to accelerating breakthrough therapies for AD.
The ADDF utilizes a unique venture philanthropy model focused on drug discovery. For over 20 years, Elan has also invested in adopting original approaches to disease modification in neurodegenerative diseases like AD. We have a common goal — to help end the life-shattering disease that not only impacts patients but also their loved ones. When we can combine our passion, energy and ingenuity, we create the opportunity to advance towards providing a cure. By joining forces, we are increasing the chances of success and ultimately benefiting millions of people.
When we started the ISOA in 1998, our goal was to create a family foundation that would fund scientists pursuing drug discovery research for AD in hopes that we could find a better way to prevent and treat this horrific disease. Through expert leadership, our Executive Director Howard Fillit, MD, has proven that providing this funding is not only necessary, but it also serves as a catalyst for scientists worldwide.

Over the years, requests for funding grew to the point where we were only able to support less than 10 percent of the proposals we received. With so many good ideas for new drugs going unfunded, we decided it was time to invite others to work with us.

During spring 2004, we founded a public charity called the Alzheimer’s Drug Discovery Foundation (ADDF). By fall, we began in earnest to build partnerships. The response was extraordinary, making 2005 a banner year of growth. We collaborated with several key organizations and raised awareness about the importance of funding AD drug discovery.

In working with our new Board of Directors, who each have a personal connection to AD, we are developing innovative ways to educate the general public. As we have learned over the past year, our best approach to conquering AD is through working together. We encourage you to join us.
During the 8 years that I was the primary caregiver for my beloved mother, I saw AD progress through many stages. At first, I wondered why this wonderful woman was changing and becoming a stranger to me. Then, the disease became more obvious. Finally, it totally enveloped her and took her from me.

When I heard about ISOA and their sole mission of funding drug discovery research for AD, I was very impressed. As I learned more about their accomplishments it led me to think that this was the type of organization that I should align with, to do whatever I can in the fight against this dreaded disease.

Since becoming President of the ADDF Board of Directors, it has been my vision to inspire people who have witnessed the tragedy of AD to work with us. We also need to increase the public’s awareness and understanding of why drug discovery is important to finding a cure; and the degree to which AD impacts patients, families, our healthcare system and economy.

I look forward to working with others whose goals are similar to mine. The only way we can end the nightmare of AD is to collectively support scientists in their research efforts to discover and develop new drugs.
“Losing my mother to AD over 7 years was difficult to watch. The sad fact was this vibrant lady slowly left me and there was nothing I could do. In my effort to get even, I discovered the ADDF. Driven by a singular mission and relentless professional management, ADDF is the most effective charity working towards solving one of the most challenging diseases of the 21st Century.”

John Cooney
Director

John Cooney is a private investor who was Founder and Chief Executive Officer of CRC Incorporated, the largest independently owned property and casualty insurance wholesaler in the United States. In 2002, CRC was sold to BBT, America’s 9th largest bank holding company. Mr. Cooney earned his BS degree in Business from Samford University of Birmingham, AL. He and wife Liz reside in Alabama, New York and Switzerland.

“Having someone close to me recently diagnosed with dementia has changed my life. Learning about the ADDF and meeting others who have witnessed this loss-of-mind illness has been a blessing. Now that I have a better understanding of memory loss diseases, I am determined to make a difference. Working with the ADDF Board to fund those on the cutting edge of a cure is my top priority.”

Joy Fishman
Director

Joy Fishman is the former Executive Director of the Pritikin Longevity Center of Miami Beach, where she oversaw the operations of the world famous diet and exercise program. Ms. Fishman holds a MS degree in Psychotherapy and a BS degree in Psychology from Barry University of Miami, FL. She and husband Jack reside in New York and Florida.
I think ADDF’s investment model is a brilliant way to run a public charity. Using for-profit business practices and recycling return on investment is a smart strategy for making the most out of limited dollars. Knowing how AD has affected my wife’s family, it made sense to join forces with the ADDF Board and help them increase their likelihood of success. I welcome others to do the same.”

Robert McNeil, PhD
Director

Robert McNeil, PhD, has over 25 years experience as an investor and management participant in seed and early-stage biomedical companies. He founded Sanderling Ventures in 1979, and serves as its Managing Director and Chair of the Partnership Committee. Dr. McNeil earned his PhD in molecular biology, biochemistry and genetics from the University of California, Irvine. He and wife Deborah reside in California and Maine.

Jon Rotenstreich
Director

Jon Rotenstreich is a managing partner of RF Partners, a financial consulting and investment firm. He is also the founding principal and Chairman of Bayer Properties, a real estate development company. Mr. Rotenstreich is a graduate of the University of Alabama (UA) and sits on many boards including UA’s President’s Cabinet. He and wife Susan reside in New York and Wyoming.
MESSAGE FROM THE EXECUTIVE DIRECTOR

ISOA and ADDF share a common mission: to fund drug discovery for AD and cognitive aging. Employing a biomedical venture philanthropy model since 1998, we have awarded $24 million for 143 programs and conferences worldwide.

Results show that our model works. ISOA-funded scientists created new classes of drugs in development for AD, screened millions of compounds, identified hundreds of leads, and demonstrated pre-clinical proof-of-concept. Their programs advanced from early-stage chemistry to clinical trials, licensing deals, company formation, late-stage financing, and public offerings. We have also received returns on our investments.

A prime example is Allon Therapeutics, Inc. After awarding a pre-clinical discovery research grant to Illana Gozes, PhD, at Tel Aviv University and receiving promising outcomes, we gave her strategic management assistance and a loan of $253,100 to found Allon in 2002. Today, the company is trading on the Toronto Stock Exchange and conducting Phase II clinical trials for AD and cognitive impairment after coronary artery bypass surgery. In December 2005, ISOA received the return of its loan and recycled it for other research.

Unfortunately, $24 million is not enough, and ISOA cannot fund the vast majority of proposals it receives. So we founded the ADDF in 2004 to enable the public to work with us. ISOA pays 90 percent of ADDF’s overhead, ensuring that all donations directly fund drug discovery research. This private foundation-public charity partnership proved highly effective in 2005.
ADDF IS AN ORGANIZATION OF
entrepreneurs
DEDICATED TO ACCELERATING AD DRUG DISCOVERY
THROUGH VENTURE PHILANTHROPY.

We collaborated with Elan Pharmaceuticals to advance our mutual mission of discovering new drugs for AD. The program received an overwhelming response of 45 proposals from 12 countries, but we were only able to fund 4. We also partnered with the National Institute on Aging (NIA) and established another AD drug discovery program that received 45 proposals. The NIA funded 5 and we will fund 3. These responses underscore the great need for funding.

We are concerned about preventing cognitive decline as well as AD. To promote cognitive health in elderly persons, we partnered with PacifiCare Health Systems to create a Cognitive Vitality Program that is now available to 180,000 people. To improve the care of AD patients, we are developing clinical practice guidelines with funding from Forest Laboratories.

We established the ADDF Board of Directors, Advisory Council and Business Development Committee, and are thankful for their commitment. We were fortunate to have many corporations, foundations and individuals contributing to our first fundraising program, resulting in raising almost $2.5 million.

As a geriatrician who has cared for thousands of people with AD, I know the tremendous burden of this illness. As a neuroscientist, I am certain that we can successfully develop effective AD drugs within 5-10 years. This historic accomplishment will transform human aging. We need your help to insure that it happens.

[Signature]
Estée Lauder  
Founder and  
Honorary Director

Leonard A. Lauder  
Co-President and Director

Ronald S. Lauder  
Co-President and Director

Howard Fillit, MD  
Executive Director  
and Director

Robert N. Butler, MD  
Director

Allan Green, MD, PhD, JD  
Director

Julia P. Gregory  
Director

Elias K. Michaelis, MD, PhD  
Director

### ADDF BOARD OF DIRECTORS

Leonard A. Lauder  
Co-Chairperson and Director

Ronald S. Lauder  
Co-Chairperson and Director

Nancy Corzine  
President and Director

Howard Fillit, MD  
Executive Director  
and Director

Suzanne Grossberg, MA  
Secretary

Joan Krupskas  
Treasurer

Joy Fishman  
Director

Robert McNeil, PhD  
Director

Jon Rotenstreich  
Director

### ADDF ADVISORY COUNCIL

Howard Cox  
Partner

Greylock

John Rowe, MD  
President and  
Chief Executive Officer

Aetna, Inc.

Andrew Schiff, MD  
Managing Director

Perseus-Sorros Biopharmaceutical Fund, L.P.

Joy Fishman  
Chair

John Rowe, MD  
President and  
Chief Executive Officer

Aetna, Inc.

Andrew Schiff, MD  
Managing Director

Perseus-Sorros Biopharmaceutical Fund, L.P.

### ADDF BUSINESS DEVELOPMENT COMMITTEE

Nancy Corzine – Chair

Howard Fillit, MD

Liz Cooney  
Joy Fishman  
Suzanne Grossberg, MA

Monika Halarewicz  
Kate Furman Pask  
Leslie Sugar

Susan Tane  
Amy Treitel

### STAFF

Howard M. Fillit, MD  
Executive Director

Suzanne Grossberg, MA  
Director of Development

Monika Halarewicz  
Communications Associate

Filomena Gomes  
Grants Writer

Wendy Ramos  
Grants and Database Manager

Peggy Quiroz  
Executive Coordinator

### SCIENTIFIC REVIEW BOARD

Paul S. Aisen, MD  
Georgetown University  
Medical Center  
Washington, DC

Ottaio Arancio, MD, PhD  
Columbia University  
New York, NY

Sanjay Asthana, MD  
University of Wisconsin  
Madison Medical School  
Madison, WI

Theodore Bashore, PhD  
University of Northern Colorado  
Greeley, CO

Paul E. Bendheim, MD  
Banner Good Samaritan Medical Center  
Phoenix, AZ

Colin B. Bier, PhD  
ABA BioResearch Inc.  
Ville St. Laurent  
Quebec, Canada

Lester I. Binder, PhD  
Northwestern University  
Medical School  
Chicago, IL
James E. Birren, PhD
UCLA Center on Aging
Los Angeles, CA

Robert D. Brinton, PhD
University of Southern California
Los Angeles, CA

Jerry Buccafusco, PhD
Prime Behavior Testing Laboratories, Inc.
Augusta, GA

Luc Buee, PhD
INSERM U422 (French National Institute for Health and Medical Research)
Lille, France

Anthony Cerami, PhD
Warren Pharmaceuticals
Ossining, NY

Greg M. Cole, PhD
VA Medical Center
Sepulveda, CA

Joseph T. Coyle, MD
Harvard Medical School
Belmont, MA

Suzanne Craft, PhD
Seattle Institute for Biomedical and Clinical Research
Seattle, WA

Keith A. Crutchley, PhD
University of Cincinnati
Cincinnati, OH

Jeffrey L. Cummings, MD
UCLA School of Medicine
Los Angeles, CA

Charles S. DeCarli, MD
University of California, Davis
Sacramento, CA

Richard Di Rocco, PhD, LLC
Secant Pharma

Karen Duff, PhD
Nathan Kline Institute
Orangeburg, NY

Christopher B. Eckman, PhD
Mayo Clinic Jacksonville
Jacksonville, FL

Elizabeth Edgery, PhD
Alzheimer’s Association of Northern California and Northern Nevada
Mountain View, CA

Alan Faden, MD
Georgetown University School of Medicine
Washington, DC

Howard Feldman, MD
University of British Columbia Hospital
Vancouver, BC

Kevin Felsenstein, PhD
Johnson & Johnson
Pharmaceutical Research & Development
Titusville, NJ

Avraham Fisher, PhD
Israel Institute for Biological Research
Neu-Ziona, Israel

Nicholas Charles Ilyas Fox, PhD
Dementia Research Centre
London, UK

Blas Frangione, MD, PhD
NYU School of Medicine
New York, NY

Richard A. Frank, MD, PhD
GE Healthcare
Princeton, NJ

Paul E. Fraser, PhD
University of Toronto
Toronto, Ontario
Canada

Douglas R. Galasko, MD
University of California, San Diego
La Jolla, CA

Elkan Gamzu, PhD
eneRGetics
Newton, MA

Jack Gauldie, PhD
McMaster University
Hamilton, Ontario
Canada

David S. Geldmacher, MD
Case Western Reserve University
School of Medicine
Cleveland, OH

Gunda I. Georg, PhD
University of Kansas
Lawrence, KS

Ezio Giacobini, MD, PhD
Geneva University Hospitals
Switzerland

Alison M. Goate, PhD
Washington University School of Medicine
St. Louis, MO

Michael Gold, MD
Johnson & Johnson
Pharmaceutical Research & Development
Titusville, NJ

Paul E. Gold, PhD
University of Illinois at Urbana-Champaign
Champaign, IL

Gunnar K. Gouras, MD
Weill Medical College of Cornell University
New York, NY

Illana Gozes, PhD
Tel Aviv University
Tel Aviv, Israel

Bryan D. Greenberg, PhD
AstraZeneca Pharmaceuticals
Wilmington, DE

Michael Grundman, MD
Elan Pharmaceuticals
San Diego, CA

John Hardy, PhD
National Institute on Aging
Bethesda, MD

Mitchell Harman, MD, PhD
Kronos Foundation
Phoenix, AZ

Joseph A. Helpenny, PhD
NYU School of Medicine
New York, NY

Orest Hurko, MD
Wyeth Research
Collegeville, PA

Michael Hutton, PhD
Mayo Clinic Jacksonville
Jacksonville, FL

Nadeem Ismaq, PhD
GE Corporate Research & Development
Niskayuna, NY

Clifford Jack, MD
Mayo Clinic College of Medicine
Rochester, MN

William Jagust, MD
University of California, Berkeley
Berkeley, CA

Jeffrey Kaye, PhD
Oregon Health & Science University
Portland, OR

Judith Kellerher-Andersson, PhD
Neuronscent, Inc.
Clarksville, MD

Robert Kisilevsky, MD, PhD
FRPC
Queen’s University
Kingston, Ontario

Paul E. Knapman, MD
Mayo Clinic College of Medicine
Rochester, MN

Amos Korczyn, MD, MSc
Tel Aviv University
Tel Aviv, Israel

Kenneth Kosik, MD
Brigham and Women’s Hospital
Boston, MA

Dora M. Kovacs, PhD
Massachusetts General Hospital
Charlestown, MA

Alan P. Kozikowski, PhD
Acenta
Arlington, VA

Arthur F. Kramer, PhD
University of Illinois
Urbana, IL

Lewis H. Kuller, PhD
University of Pittsburgh Medical Center
Pittsburgh, PA

Frank M. LaFerla, PhD
University of California, Irvine
Irvine, CA

Deborah Lahiri, PhD
Indiana University School of Medicine
Indianapolis, IN

Gary Landreth, PhD
Case Western Reserve University
School of Medicine
Cleveland, OH

Lit-Fui Lau, PhD
Pfizer Inc.
Groton, CT

Virginia M. Y. Lee, PhD
University of Pennsylvania
Philadelphia, PA

Frank M. Longo, MD, PhD
University of North Carolina School of Medicine
Chapel Hill, NC

Rebekah Loy, PhD
University of Rochester
Rochester, NY

Eckhard Mandelkow, PhD
Max-Planck-Unit for Structural Molecular Biology
Hamburg, Germany

Eva-Maria Mandelkow, MD, PhD
Max-Planck-Unit for Structural Molecular Biology
Hamburg, Germany

Charles J. Manly, PhD
Neurogen Corporation
Branford, CT
Michael W. Wolfe, PhD  
Brigham and  
Women's Hospital  
Boston, MA

Tony Wyss-Coray, PhD  
Stanford University  
Stanford, CA

Austin Yang, PhD  
University of Southern California  
Los Angeles, CA

Mousa B.H. Youdim, PhD  
Technion  
Haifa, Israel

***

BUSINESS ADVISORY BOARD

John K. Clarke  
Cardinal Partners  
Princeton, NJ

Julie Eskay-Eagle  
September Ventures LLC  
Cos Cob, CT

Emer Leahy, PhD  
Psychogenics Inc.  
Hawthorne, NY

Debra Peattie, PhD  
Valeo Peattie, PhD  
Concord, MA

Mark A. Cochran, PhD  
NeuroVentures Capital, LLC  
Charlottesville, VA

Stephen M. Goldberg, PhD  
The Channel Group  
New York, NY

Michael Lytton, PhD  
Oxford Bioscience Partners  
Boston, MA

Cathrin Petty  
Apax Partners & Co.  
London, England

Matthew S. Crawford  
Cockrell Interests, Inc.  
Houston, TX

Stephen M. Goodman, Esq.  
Pryor Cashman Sherman & Flynn, LLP  
New York, NY

Robert G. Nagro  
ITF Global Partners  
New York, NY

Barbara J. Dalton, PhD  
EuclidSR Partners  
New York, NY

Elaine Jones, PhD  
EuclidSR Partners  
New York, NY

Daniel J. O'Connell  
NeuroVentures Capital, LLC  
Charlottesville, VA

Rana Quraishi, PhD  
Standard & Poor's  
New York, NY

Steven G. Dickman  
CBT Advisors  
Cambridge, MA

Perry Kassen  
Celsius Corporation  
Summit, NJ

William Paiva  
Chisolo Private Capital  
Tula, OK

Doug A. Zingale  
Greenberg Traurig, LLP  
Boston, MA

Jeff Dobro, MD  
Creative Medical Management, Inc.  
Boonton Twp., NJ

Glenn J. Kline  
Academy Funds  
Research Triangle Park, NC

Lynne H. Parker, PhD  
Trillium Medical Ventures, LLC  
New York, NY

Cathrin Petty  
Apax Partners & Co.  
London, England

John K. Clarke  
Cardinal Partners  
Princeton, NJ

Joseph K. Belanoff, MD  
Corcept Therapeutics, Inc.  
Menlo Park, CA

Robert D. Brinton, PhD  
University of Southern California  
Los Angeles, CA

Mousa B.H. Youdim, PhD  
Technion  
Haifa, Israel

Ottavio Arancio, MD, PhD  
Nathan Kline Institute  
Orangeburg, NY

Calpain: A Treatment of Alzheimer's Disease  
Award: $121,126  
Duration: 2000 – 2001

Ottavio Arancio, MD, PhD  
Nathan Kline Institute  
Orangeburg, NY

Calpain: A Treatment of Alzheimer's Disease  
Award: $121,126  
Duration: 2000 – 2001

Ottavio Arancio, MD, PhD  
Nathan Kline Institute  
Orangeburg, NY

Calpain: A Treatment of Alzheimer's Disease  
Award: $121,126  
Duration: 2000 – 2001

Ottavio Arancio, MD, PhD  
Nathan Kline Institute  
Orangeburg, NY

Calpain Inhibitor: A Treatment of Alzheimer's Disease - Part 2  
Award: $88,205  
Duration: 2003 – 2005

Ettienne-Emile Baulieu, PhD  
MAPREG  
Le Kremlin-Bicetre  
Cedex France  
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases  
Award: $150,000  
Duration: 2002 – 2003

Joseph K. Belanoff, MD  
Corcept Therapeutics, Inc.  
Menlo Park, CA

Robert D. Brinton, PhD  
University of Southern California  
Los Angeles, CA

Luce Brue, PhD  
INSERM U422 (French National Institute for Health and Medical Research)  
Lille, France

Tony Wyss-Coray, PhD  
Stanford University  
Stanford, CA

Development of Drugs for a New Therapeutic Target in Alzheimer's Disease  
Award: $100,000  
Duration: 2002 – 2003

Jerry Buccafusco, PhD  
Prime Behavior Testing Laboratories, Inc.  
Augusta, GA

Robert Diaz Brinton, PhD  
University of Southern California  
Los Angeles, CA

A Novel Method of Cell-Mediated Therapy for Alzheimer's Disease  
Award: $75,000  
Duration: 2005 – 2006

Le Kremlin-Bicetre  
Cedex France  
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases  
Award: $150,000  
Duration: 2002 – 2003

Ettienne-Emile Baulieu, PhD  
MAPREG  
Le Kremlin-Bicetre  
Cedex France  
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases  
Award: $150,000  
Duration: 2002 – 2003

Ettienne-Emile Baulieu, PhD  
MAPREG  
Le Kremlin-Bicetre  
Cedex France  
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases  
Award: $150,000  
Duration: 2002 – 2003

John K. Clarke  
Cardinal Partners  
Princeton, NJ

Slowing the Progression of Cognitive Decline in Alzheimer's Disease Using Mempristone  
Award: $462,929  
Duration: 2001 – 2003

Dale E. Breidenstein, PhD  
Buck Institute for Age Research  
Novato, CA

Screening for Alzheimer's Therapeutics Based on a Novel Target  
Award: $100,000  
Duration: 2004

Jerry Buccafusco, PhD  
Prime Behavior Testing Laboratories, Inc.  
Augusta, GA

A Computer-Assisted Cognitive Test Battery for Aged Monkey  
Award: $112,947  
Duration: 2001 – 2003

Ettienne-Emile Baulieu, PhD  
MAPREG  
Le Kremlin-Bicetre  
Cedex France  
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases  
Award: $150,000  
Duration: 2002 – 2003

Ettienne-Emile Baulieu, PhD  
MAPREG  
Le Kremlin-Bicetre  
Cedex France  
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases  
Award: $150,000  
Duration: 2002 – 2003

Ettienne-Emile Baulieu, PhD  
MAPREG  
Le Kremlin-Bicetre  
Cedex France  
Control of Microtubule Assembly in the Nervous System: Novel Approach for the Prevention and Treatment of Neurodegenerative Diseases  
Award: $150,000  
Duration: 2002 – 2003
Michael Hutton, PhD
Mayo Clinic Jacksonville
Jacksonville, FL

In Vivo Testing of Compounds that Block the Development of Neurofibrillary Tangle Pathology
Award: $196,662
Duration: 2004 – 2006

Khalid Iqbal, PhD
NY State Institute for Basic Research in Developmental Disabilities
New York, NY

Screening Assays to Inhibit Alzheimer Neurofibrillary Degeneration
Award: $528,869
Duration: 2000 – 2004

Lee-Way Jin, MD, PhD
University of Washington
Seattle, WA

The Amelioration of A-Beta Aggregation and Cell Toxicity by Tricyclic Pyrone Compounds
Award: $50,000
Duration: 2000 – 2001

June Kososhita
Alzheimer Research Forum Foundation
Waltham, MA

Alzheimer Cheminformatics Resource
Award: $60,275
Duration: 2004 – 2006

Robert Kishlevsky, MD, PhD
FRCPQ, Queen's University
Kingston, Ontario, Canada

Novel Glycaminoglycan Precursor As Anti-Amyloid Agent
Award: $245,300
Duration: 2000 – 2003

Novel Glycaminoglycan (GAG) Precursors as Anti-Amyloid Agents - Part 2
Award: $191,220
Duration: 2003 – 2004

Kenneth Kosik, MD
Brigham and Women's Hospital
Boston, MA

Identifying Drugs that Inhibit Kinase-Induced Dissociation of Tau from Microtubules
Award: $130,000
Duration: 2001 – 2002

The Development of CDK5 Inhibitors
Award: $199,000
Duration: 2004 – 2005
In Vivo Analysis of Effects of Microtubule-Stabilizing Drugs in Tau Mutant Mice
Award: $258,352
Duration: 2003 – 2006
Suzana Petanceska, PhD
Nathan Kline Institute
Orangeburg, NY
Pharmacogenetic Effects of Human apoE on the Amyloid-Reducing Activity of Cholesterol Lowering Drugs in a Transgenic Mouse Model for Alzheimer’s Disease
Award: $360,742
Duration: 2000 – 2003
Efficacy of Oral Heparin Treatment for Alzheimer’s Disease
Award: $98,565
Duration: 2003 – 2004
Leonard Pitruecelli, PhD
Mayo Clinic Jacksonville
Jacksonville, FL
Hyp70 Activity and Tau A Therapeutic Target
Award: $125,000
Duration: 2004 – 2005
Ram Rambahadran, PhD
Tranzyme Pharma, Inc.
Research Triangle Park, NC
Cell Culture Models and Animal Models of Alzheimer’s Disease
Award: $493,550
Duration: 2003 – 2005
Clara M. Regan, PhD, DSc
University College Dublin
Belfield, Dublin
Ireland
Determination of the Effect of Chronic Administration of ABS-205 on Morris Water Maze Learning in the Aged Rat
Award: $50,000
Duration: 2000
Peter B. Reiner, VMD, PhD
Active Pass Pharmaceuticals
Vancouver, BC
Canada
Brain-Expressed ABC Transporters as Targets for AD Therapeutics
Award: $150,000
Duration: 2000 – 2001
Elliott Richelson, MD
Mayo Clinic Jacksonville
Jacksonville, FL
Peptide Nucleic Acids Targeted to the Amyloid Precursor Protein
Award: $200,000
Duration: 2001 – 2003
Jack T. Rogers, PhD
Massachusetts General Hospital
Charlestown, MA
A New Translational Regulatory Target in the Alzheimer’s APP Transcript
Award: $100,000
Duration: 2000 – 2002
Alzheimer’s Disease Drug Discovery Targeted to the APP-mRNA 5’ Untranslated Region
Award: $96,734
Duration: 2001 – 2003
Small Molecule Drug Discovery Targeted To The Alzheimer’s APP-mRNA 5’ Untranslated Region
Award: $100,000
Duration: 2003 – 2005
Kumar Sanmamuri, PhD
Medical University of South Carolina
Charleston, SC
Evaluation of GPI-Anchored Proteins as Targets for Inhibition of Beta-Secretase
Award: $200,000
Duration: 2000 – 2002
Steven Schreiber, MD
University of California, Irvine
Irvine, CA
Efficacy of the Histone Deacetylase Inhibitor, SAHA, in AD Transgenic Mice - A Proof-of-Concept Study
Award: $130,000
Duration: 2006 – 2007
Michael L. Shleeski, MD, PhD
Columbia University
New York, NY
Pharmacological Reversal of the Behavioral and Electrical Sequelae of A-Beta Deposition
Award: $50,000
Duration: 2004 – 2005
Jonathan D. Smith, PhD
The Cleveland Clinic Foundation
Cleveland, OH
Estrogen and ApoE: Interaction and Effect on Pathogenesis in a Mouse Model of Alzheimer’s Disease
Award: $416,130
Duration: 1999 – 2002
Drug Discovery: Estrogen Related Compounds in Mouse Models of Alzheimer’s Disease
Award: $90,000
Duration: 2003 – 2004
Reka Solomon, PhD
Tel Aviv University
Tel Aviv, Israel
A Novel Approach Towards Vaccination Against Alzheimer Beta-Amyloid Peptide
Award: $100,000
Duration: 2002 – 2004
Wolfgang J. Streit, PhD
University of Florida
Gainesville, FL
Role of Fractalkine in Regulating Neurinomicroglia Interactions
Award: $126,492
Duration: 2003 – 2005
Sidney Strickland, PhD
The Rockefeller University
New Haven, CT
Analysis of the Role to tPA and Plasmino(gen) in Alzheimer’s Disease
Award: $256,480
Duration: 2001 – 2003
Stephen M. Streitmatter, PhD
Yale University Medical School
New Haven, CT
Nogo Antagonist in Axon Regeneration and Plasticity
Award: $267,928
Duration: 2001 – 2003
Joel L. Sussman, PhD
The Weizmann Institute of Science
Rehovot, Israel
Structural and Functional Analysis of Beta Secretase as a Potential Target for Therapeutic Intervention in Alzheimer’s Disease
Award: $312,555
Duration: 2002 – 2005
Jordan Tang, PhD
Zapaq, Inc.
Oklahoma City, OK
Studies on Human Memapsin 2 (Beta-Secretase): Prerequisite of Drug Design for Alzheimer’s Disease
Award: $500,000
Duration: 2002 – 2003
Founders Program: Studies on Human Memapsin 2 (Beta-Secretase): Drug Design for Alzheimer’s Disease
Award: $250,000
Duration: 2002 – 2004
Rudolph E. Tanski, PhD
Massachusetts General Hospital
Charlestown, MA
Small Molecule Therapeutics for Alzheimer’s Disease
Award: $340,000
Duration: 2001 – 2004
Greg R., J. Thatcher, PhD
University of Illinois, Chicago
Chicago, IL
Generation and Optimization of NO Mimetics for Treatment of Alzheimer’s Disease
Award: $150,000
Duration: 2004 – 2005
Generation and Optimization of NO mimetics for Treatment of Alzheimer’s Disease—Part 2
Award: $130,000
Duration: 2006 – 2007
Tim Tulley, PhD
Helicon Therapeutics
Cold Spring Harbor, NY
CREB and the Discovery of Cognitive Enhancers
Award: $238,780
Duration: 2001 – 2002
Duane L. Venton, PhD
University of Illinois, Chicago
Chicago, IL
A Combinatorial Search for Beta-Cyclodextrins to Abate the Neurotoxicity of Amyloid-Beta-Peptide in Alzheimer’s Disease
Award: $311,916
Duration: 2001 – 2004
D. Martin Watterson, PhD  
Northwestern University  
Medical School  
Chicago, IL  
Ligands that Suppress Neuroinflammatory Responses  
Award: $476,278  
Duration: 2001 – 2004

Novel Therapeutics Targeting Neuroinflammation  
Award: $140,000  
Duration: 2005 – 2006

Nicholas Webster, PhD  
Veteran’s Medical Research Foundation  
San Diego, CA  
Development of Cell-Permeable NGF Mimetics  
Award: $130,000  
Duration: 2006 – 2007

Maria Weinstock-Rosin, PhD  
Hebrew University  
Medical Centre  
Jerusalem, Israel  
Award for Major Scientific Achievement in Drug Discovery and Development for Alzheimer’s Disease  
Award: $100,000  
Duration: 2004 – 2005

Manfred Windisch, PhD  
JSW-Research Forschungslabor GmbH  
Graz, Austria  
Development of a New Treatment for Alzheimer’s Disease and Parkinson’s Disease using Anti-Aggregatory Beta-Synuclein Derived Peptides  
Award: $260,000  
Duration: 2002 – 2004

Michael W. Wolfe, PhD  
Brigham and Women’s Hospital  
Boston, MA  
Helical Peptidomimetics as Inhibitors of Alzheimer’s Gamma-Secretase  
Award: $147,067  
Duration: 2000 – 2002

Tony Wyss-Coray, PhD  
Stanford University  
Stanford, CA  
The TGF-Beta Pathway as a Therapeutic Target to Treat Alzheimer’s Disease  
Award: $152,232  
Duration: 2003 – 2004

John R. Wyss-Coray, PhD  
Stanford University  
Stanford, CA  
The TGF-Beta Pathway as a Therapeutic Target to Treat Alzheimer’s Disease  
Award: $152,300  
Duration: 2004 – 2005

Daniel G. Chain, PhD  
Mindset BioPharmaceuticals (USA) Inc.  
New York, NY  
Drug Development for AD: Development of New Antioxidants  
Award: $524,018  
Duration: 2000 – 2002

Carl W. Cotman, PhD  
University of California, Irvine, Irvine, CA  
Phase I Pilot Study of Combination Antioxidants in Aging  
Award: $100,000  
Duration: 2002 – 2003

Suzanne Craft, PhD  
Seattle Institute for Biomedical and Clinical Research (SIBCR)  
Seattle, WA  
Intranasal Insulin Administration and Memory in AD  
Award: $181,516  
Duration: 2003 – 2006

John F. DeBernardis, PhD  
Molecular Geriatrics Corporation  
Vernon Hill, IL  
Novel Therapeutic Screening Technology for Alzheimer’s Disease  
Award: $51,470  
Duration: 2000 – 2001

Charles S. DeCarli, MD  
University of California, Davis Sacramento, CA  
Clinical Interpretation of MRI to Predict Conversion of Mild Cognitive Impairment to Dementia  
Award: $35,000  
Duration: 2003 – 2004

Steven A. Johnson, PhD  
Cortex Pharmaceuticals, Inc.  
Irvine, CA  
Randomized, Double-Blind Clinical Study of Ampalex (CX516) in Patients with Mild Cognitive Impairment  
Award: $247,500  
Duration: 2000 – 2002

Mei-Ping Kung, PhD  
University of Pennsylvania Philadelphia, PA  
Inhibitors of Beta Amyloid Aggregates: Characterization of Radio-ordinated Ligands of Beta-Amyloid  
Award: $263,521  
Duration: 2000 – 2002

Evaluation of Anti-Plaque Treatment for Alzheimer’s Disease  
Award: $90,000  
Duration: 2003 – 2004

Bruce L. Miller, MD  
UCLA Memory and Aging Center  
Los Angeles, CA  
UCSF Investigation of the Effects of Testosterone on Cognition in Male Patients with Mild Alzheimer’s Disease  
Award: $150,000  
Duration: 2003 – 2004

Peter J. Neumann, DSc  
Harvard School of Public Health  
Boston, MA  
Public Attitudes Towards Genetic Testing in Alzheimer’s Disease  
Award: $77,072  
Duration: 2001

John M. Ringman, MD  
UCLA School of Medicine  
Los Angeles, CA  
A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Three Doses of Curcumin Versus Placebo in Patients with Mild to Moderate Alzheimer’s Disease  
Award: $299,451  
Duration: 2003 – 2006

Mary Sano, PhD  
Mount Sinai Medical Center  
New York, NY  
Effect of High-Dose Supplements on Blood Homocysteine in Alzheimer’s Disease  
Award: $178,801  
Duration: 2000 – 2001

Barbara B. Sherwin, PhD  
McGill University  
Verdun, Quebec Canada  
Effects of Estradiol on Cognitive Function in Elderly Men with Mild Cognitive Impairment  
Award: $186,000  
Duration: 1999 – 2004

Berislav Zlokovic, MD, PhD  
University of Rochester Rochester, NY  
Blockers of RAGE/Amyloid-Beta Interaction at the Blood Brain Barrier  
Award: $165,723  
Duration: 2004 – 2005

Blockers of RAGE/Amyloid-Beta Interaction at the Blood Brain Barrier  
Award: $130,000  
Duration: 2006 – 2007

***

Funded Programs

Clinical

\[
\text{Daniel G. Chain, PhD}  
\text{Mindset BioPharmaceuticals (USA) Inc.}  
\text{New York, NY}  
\text{Drug Development for AD: Development of New Antioxidants}  
\text{Award: $524,018}  
\text{Duration: 2000 – 2002}
\]

\[
\text{Carl W. Cotman, PhD}  
\text{University of California, Irvine, Irvine, CA}  
\text{Phase I Pilot Study of Combination Antioxidants in Aging}  
\text{Award: $100,000}  
\text{Duration: 2002 – 2003}
\]

\[
\text{Suzanne Craft, PhD}  
\text{Seattle Institute for Biomedical and Clinical Research (SIBCR)}  
\text{Seattle, WA}  
\text{Intranasal Insulin Administration and Memory in AD}  
\text{Award: $181,516}  
\text{Duration: 2003 – 2006}
\]

\[
\text{John F. DeBernardis, PhD}  
\text{Molecular Geriatrics Corporation}  
\text{Vernon Hill, IL}  
\text{Novel Therapeutic Screening Technology for Alzheimer’s Disease}  
\text{Award: $51,470}  
\text{Duration: 2000 – 2001}
\]

\[
\text{Charles S. DeCarli, MD}  
\text{University of California, Davis Sacramento, CA}  
\text{Clinical Interpretation of MRI to Predict Conversion of Mild Cognitive Impairment to Dementia}  
\text{Award: $35,000}  
\text{Duration: 2003 – 2004}
\]

\[
\text{Steven A. Johnson, PhD}  
\text{Cortex Pharmaceuticals, Inc.}  
\text{Irvine, CA}  
\text{Randomized, Double-Blind Clinical Study of Ampalex (CX516) in Patients with Mild Cognitive Impairment}  
\text{Award: $247,500}  
\text{Duration: 2000 – 2002}
\]

\[
\text{Mei-Ping Kung, PhD}  
\text{University of Pennsylvania Philadelphia, PA}  
\text{Inhibitors of Beta Amyloid Aggregates: Characterization of Radio-ordinated Ligands of Beta-Amyloid}  
\text{Award: $263,521}  
\text{Duration: 2000 – 2002}
\]

\[
\text{Evaluation of Anti-Plaque Treatment for Alzheimer’s Disease}  
\text{Award: $90,000}  
\text{Duration: 2003 – 2004}
\]

\[
\text{Bruce L. Miller, MD}  
\text{UCLA Memory and Aging Center}  
\text{Los Angeles, CA}  
\text{UCSF Investigation of the Effects of Testosterone on Cognition in Male Patients with Mild Alzheimer’s Disease}  
\text{Award: $150,000}  
\text{Duration: 2003 – 2004}
\]

\[
\text{Peter J. Neumann, DSc}  
\text{Harvard School of Public Health}  
\text{Boston, MA}  
\text{Public Attitudes Towards Genetic Testing in Alzheimer’s Disease}  
\text{Award: $77,072}  
\text{Duration: 2001}
\]

\[
\text{John M. Ringman, MD}  
\text{UCLA School of Medicine}  
\text{Los Angeles, CA}  
\text{A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Three Doses of Curcumin Versus Placebo in Patients with Mild to Moderate Alzheimer’s Disease}  
\text{Award: $299,451}  
\text{Duration: 2003 – 2006}
\]

\[
\text{Mary Sano, PhD}  
\text{Mount Sinai Medical Center}  
\text{New York, NY}  
\text{Effect of High-Dose Supplements on Blood Homocysteine in Alzheimer’s Disease}  
\text{Award: $178,801}  
\text{Duration: 2000 – 2001}
\]

\[
\text{Barbara B. Sherwin, PhD}  
\text{McGill University}  
\text{Verdun, Quebec Canada}  
\text{Effects of Estradiol on Cognitive Function in Elderly Men with Mild Cognitive Impairment}  
\text{Award: $186,000}  
\text{Duration: 1999 – 2004}
\]
Arthur F. Kramer, PhD
University of Illinois
Urbana, IL
Influence of Fitness on the
Neurodegenerative Function
of Older Adults
Award: $433,054
Duration: 2001 – 2004
Enhancing Cognitive and Brain
Function of Older Adults
Through Fitness Training
Award: $100,000
Duration: 2005 – 2006

John P. Blass, MD, PhD
Burke Medical
Research Institute
White Plains, NY
Nutritional Treatment for AD
Award: $100,250
Duration: 1999 – 2000
Nutritional Treatment for AD (Part 2)
Award: $80,210
Duration: 2000

D. Larry Sparks, PhD
Sun Health Research Institute
Sun City, AZ
A Phase II Trial Investigating
the Effect of the HMG-CoA
Reductase Inhibitor
Atorvastatin Calcium (Lipitor)
in the Treatment of
Alzheimer’s Disease
Award: $450,000
Duration: 2000 – 2003

Jun Tan, PhD
University of South Florida
Tampa, FL
Green Tea Epigallocatechin-3-
Gallate (EGCG) Modulates
Amyloid Precursor Protein
Cleavage and Reduces
Amyloidosis in Alzheimer’s
Transgenic Mice
Award: $74,810
Duration: 2005 – 2006

Mark H. Tuszyński, MD
University of California,
San Diego
La Jolla, CA
A Phase I Study of Nerve
Growth Factor Ex Vivo Gene
Therapy for Alzheimer’s Disease
Award: $402,113
Duration: 2000 – 2003

Marc E. Weksler, PhD
Weill Medical College of
Cornell University
New York, NY
Human Anti-A Beta
Antibodies for the Treatment
of Alzheimer’s Disease
Award: $80,210
Duration: 2002

John B. Zabriskie, MD
The Rockefeller University
New York, NY
Is Variation in the Production
of TNF - In Elderly Pre-
Operative Patients Predictive
of Post-Operative Cognitive
Complications
Award: $86,335
Duration: 1999 – 2000

John P. Blass, MD, PhD
Burke Medical
Research Institute
White Plains, NY
Enhancing Cognitive and Brain
Function of Older Adults
Through Fitness Training
Award: $100,000
Duration: 2005 – 2006

Funded Programs
Prevention

Arthur F. Kramer, PhD
University of Illinois
Urbana, IL
Influence of Fitness on the
Neurodegenerative Function
of Older Adults
Award: $433,054
Duration: 2001 – 2004
Enhancing Cognitive and Brain
Function of Older Adults
Through Fitness Training
Award: $100,000
Duration: 2005 – 2006

Thomas T. Perls, MD
Boston University School
of Medicine
Boston, MA
Identifying Genes Predisposing
to Successful Cognitive Aging
Award: $522,132
Duration: 1999 – 2002

John B. Zabriskie, MD
The Rockefeller University
New York, NY
Is Variation in the Production
of TNF - In Elderly Pre-
Operative Patients Predictive
of Post-Operative Cognitive
Complications
Award: $86,335
Duration: 1999 – 2000

Funded Programs
Early Detection

Robert P. Friedland, MD
Case Western Reserve
University School of Medicine
Cleveland, OH
Genetic and Environmental
Risk Factors for Alzheimer’s
Disease in Israeli Arabs
Award: $50,000
Duration: 1999 – 2000
Genetic and Environmental
Risk Factors for Alzheimer’s
Disease in Israeli Arabs (Part 2)
Award: $210,000
Duration: 2000 – 2003

Mark A. Gluck, PhD
Rutgers University - Newark
Newark, NJ
Novel Behavioral Screening
Tools for Memory Assessment in
Rodents and Humans
Award: $45,000
Duration: 2005 – 2006

Jeffrey L. Cummings, MD
UCLA School of Medicine
Los Angeles, CA
Multicenter Analysis of
Hippocampal Morphology
in MCI
Award: $300,000
Duration: 2000 – 2002

Mony deLeon, EdD
NYU School of Medicine
New York, NY
MRI and CSF Tau Protein
Levels: An Early Screening Test
for Alzheimer’s Disease
Award: $85,000
Duration: 1999 – 2001

David Knopman, MD
Mayo Clinic College
of Medicine
Rochester, MN
Telephonic Screening for
Cognitive Impairment
Award: $5,828
Duration: 2000

Ely Simon, MD
NeuroTrax Corporation
Bayside, NY
Mindstreams Cognitive Testing
for Early Diagnosis and
Longitudinal Follow-up of
Dementia: A 3-Center
Validation Study
Award: $319,711
Duration: 2003 – 2006

David Knopman, MD
Mayo Clinic College
of Medicine
Rochester, MN
Telephonic Screening for
Cognitive Impairment
Award: $5,828
Duration: 2000
FUNDED PROGRAMS

**ADDF/ISOA PARTNERSHIP PROGRAMS**

**Alzheimer's Research Consortium (ARC)**

- New Animal Models for Alzheimer's Disease
  - Award: $200,000
  - Duration: 2003 – 2005

**Alzheimer's Research Consortium (ARC)**

- Emory: Transgenic Rat Model of Alzheimer's Disease
  - Award: $500,000
  - Duration: 2004

- Harvard: Novel Fly and Mouse Models for the P25/CDK5 Kinase
  - Award: $100,000
  - Duration: 2005 – 2006

**Elan Pharmaceuticals, Inc.**

- San Diego, CA
  - Novel Approaches to Drug Discovery for Alzheimer's Disease
    - Award: $500,000
    - Duration: 2005 – 2008

**National Institute on Aging**

- Bethesda, MD
  - Partnership Grant between ISOA, NIA and NINDS: Grants for Alzheimer's Disease Drug Discovery
    - Award: $300,000
    - Duration: 2005 – 2007

**NIH Alzheimer's Disease Neuroimaging Initiative**

- Award: $100,000
- Duration: 2005

***

**FUND PROGRAMS**

**Grant Awarded Conferences**

- Robert N. Butler, MD
  - International Longevity Center (ILC)
  - New York, NY
  - The Aging Factor in Health and Disease: An Interdisciplinary Workshop for Scientists
    - Award: $9,000
    - Duration: 1999
  - Biomarkers of Aging Workshop
    - Award: $10,000
    - Duration: 2000
  - Workshop on Longevity Genes: From Primitive Organisms to Man
    - Award: $5,000
    - Duration: 2001

- Scott A. Small, MD
  - Columbia University
  - New York, NY
  - Imaging Mouse Models of Alzheimer's Disease
    - Award: $92,733
    - Duration: 2003 – 2004

- D. Larry Sparks, PhD
  - Sun Health Research Institute
  - Sun City, AZ
  - Is Elevated Serum Cholesterol Predictive of Developing AD?
    - Award: $346,372
    - Duration: 2001 – 2006

- Leon J. Thal, MD
  - University of California, San Diego
  - La Jolla, CA
  - Utility of MRI to Predict Progression from MCI to AD and Treatment Response to Vitamin E and Donepezil
    - Award: $399,890
    - Duration: 1999 – 2004

- Yanming Wang, PhD
  - University of Illinois, Chicago
  - Chicago, IL
  - Amyloid Probes in Aging and Alzheimer's Disease: Dual Agents for Both PET and SPECT
    - Award: $197,000
    - Duration: 2001 – 2005

- Philip Scheltens, PhD
  - VU University Medical Center
  - Amsterdam, The Netherlands
  - Functional Connectivity in Elderly Controls and Alzheimer's Patients Using Resting State fMRI: A Pilot Study
    - Award: $85,550
    - Duration: 2003 – 2004

- Gary W. Small, MD
  - UCLA Neuropsychiatric Institute
  - Los Angeles, CA
  - FDDNP-PET Imaging for Early Detection of Alzheimer's Disease
    - Award: $200,000
    - Duration: 2000 – 2003

- Robert P. Friedland, MD
  - Case Western Reserve University School of Medicine
  - Cleveland, OH
  - International Symposium on Alzheimer's Disease in Middle East
    - Award: $20,000
    - Duration: 2001

- Joyce Chase
  - Yale University Medical School
  - New Haven, CT
  - Cognition Enhancers, Anti-Alzheimer and Neuroprotective Drugs' Symposium
    - Award: $5,000
    - Duration: 2000

- Avraham Fisher, PhD
  - Israel Institute for Biological Research
  - Ness-Ziona, Israel
  - The 11th International Symposium on Cholinergic Mechanisms - Function and Dysfunction
    - Award: $5,000
    - Duration: 2001

- Moussa B. Youdim, PhD
  - Technion
  - Haifa, Israel
  - Development and Molecular Mechanism of Neuroprotective Activity of Novel Bifunctional Cholinesterase-monoamine Oxidase Inhibitor-iron Chelators for the Treatment of Alzheimer's Disease and Lezky Body Disease
    - Award: $75,000
    - Duration: 2005 – 2006

- Gary W. Small, MD
  - UCLA Neuropsychiatric Institute
  - Los Angeles, CA
  - FDDNP-PET Imaging for Early Detection of Alzheimer's Disease
    - Award: $200,000
    - Duration: 2000 – 2003

- Leon J. Thal, MD
  - University of California, San Diego
  - La Jolla, CA
  - Utility of MRI to Predict Progression from MCI to AD and Treatment Response to Vitamin E and Donepezil
    - Award: $399,890
    - Duration: 1999 – 2004

- Yanming Wang, PhD
  - University of Illinois, Chicago
  - Chicago, IL
  - Amyloid Probes in Aging and Alzheimer's Disease: Dual Agents for Both PET and SPECT
    - Award: $197,000
    - Duration: 2001 – 2005

- Philip Scheltens, PhD
  - VU University Medical Center
  - Amsterdam, The Netherlands
  - Functional Connectivity in Elderly Controls and Alzheimer's Patients Using Resting State fMRI: A Pilot Study
    - Award: $85,550
    - Duration: 2003 – 2004

- Gary W. Small, MD
  - UCLA Neuropsychiatric Institute
  - Los Angeles, CA
  - FDDNP-PET Imaging for Early Detection of Alzheimer's Disease
    - Award: $200,000
    - Duration: 2000 – 2003

- Robert P. Friedland, MD
  - Case Western Reserve University School of Medicine
  - Cleveland, OH
  - International Symposium on Alzheimer's Disease in Middle East
    - Award: $20,000
    - Duration: 2001

- Joyce Chase
  - Yale University Medical School
  - New Haven, CT
  - Cognition Enhancers, Anti-Alzheimer and Neuroprotective Drugs' Symposium
    - Award: $5,000
    - Duration: 2000

- Avraham Fisher, PhD
  - Israel Institute for Biological Research
  - Ness-Ziona, Israel
  - The 11th International Symposium on Cholinergic Mechanisms - Function and Dysfunction
    - Award: $5,000
    - Duration: 2001

- Moussa B. Youdim, PhD
  - Technion
  - Haifa, Israel
  - Development and Molecular Mechanism of Neuroprotective Activity of Novel Bifunctional Cholinesterase-monoamine Oxidase Inhibitor-iron Chelators for the Treatment of Alzheimer's Disease and Lezky Body Disease
    - Award: $75,000
    - Duration: 2005 – 2006
Ezio Giacobini, MD, PhD  
Geneva University Hospitals  
Switzerland

Seventh International  
Geneva/Springfield Symposium  
on Advances in  
Alzheimer's Therapy
Award: $5,000  
Duration: 2002

8th International  
Montreal/Springfield Symposium on Advances in  
Alzheimer's Therapy
Award: $5,000  
Duration: 2003

Yael Goshen, PhD  
The Alzheimer's Association of Israel (AAI)  
Ramar - Gan, Israel
The First Israeli Consensus Conference on the Issue of  
The Treatment of Alzheimer Patients in Israel  
Award: $10,000  
Duration: 2002

Illana Gozes, PhD  
Tel Aviv University  
Tel Aviv, Israel
Summer Neuropeptide 2003 Conference  
Award: $5,000  
Duration: 2003

Naim M. Gribaa  
The Jewish Home & Hospital-Life Care System  
New York, NY
Alzheimer's Conference  
Award: $2,500  
Duration: 2003

Israel Hanin, PhD  
Loyola University Chicago-Maywood, IL
Alzheimer's and Parkinson's Disease: New Perspectives 6th International Conference  
Award: $5,000  
Duration: 2003

Amos Korczyn, MD, MSc  
Tel Aviv University  
Tel Aviv, Israel
Second International Congress on Vascular Dementia  
Award: $5,000  
Duration: 2002

Third International Congress on Vascular Dementia  
Award: $5,000  
Duration: 2003

Marc P. Mattson, PhD  
National Institute on Aging Gerontology Research Center  
Baltimore, MD
Successful Aging: 30th Annual Meeting of the American Aging Assoc., 15th Annual Meeting of the American College of Clinical Gerontology  
Award: $4,000  
Duration: 2001

Ron C. Peck  
Neurological Disease Foundation  
Burlingame, CA
Challenging Views of Alzheimer's Disease  
Award: $2,500  
Duration: 2005

Mark E. Toole, PhD  
Wake Forest Health Sciences  
Winston-Salem, NC
Planning for A Prospective, Randomized Study for the Prevention & Treatment of Post-Stroke Dementia  
Award: $7,500  
Duration: 2002

Michael W. Weiner, MD  
Northern California Institute for Research and Education (NCIRE)  
San Francisco, CA
Neuroimaging of Alzheimer’s Disease and Related Disorders’ Satellite Meeting  
Award: $5,000  
Duration: 2000

Manfred Windisch, PhD  
JSW-Research Forschungslabor GmbH  
Graz, Austria
5th International Conference on Aging and Dementia - Current and Future Concepts  
Award: $5,000  
Duration: 2001

---

**Funded Programs**

**Partnership Sponsored Conferences**

<table>
<thead>
<tr>
<th>Event Description</th>
<th>Organizer</th>
<th>Location</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Second Annual Investigators' Meeting</td>
<td>Naim M. Gribaa</td>
<td>The Jewish Home &amp; Hospital-Life Care System, New York, NY</td>
<td>2001</td>
</tr>
<tr>
<td>Third Annual Investigators' Meeting</td>
<td>Israel Hanin</td>
<td>Loyola University Chicago-Maywood, IL</td>
<td>2002</td>
</tr>
<tr>
<td>Neurofibrillary Tangles as a Target for Developing New Therapeutics for AD</td>
<td>Amos Korczyn</td>
<td>Tel Aviv University, Tel Aviv, Israel</td>
<td>2002</td>
</tr>
<tr>
<td>Apolipoprotein E as a Target for Developing New Therapeutics for Alzheimer's Disease</td>
<td>Marc P. Mattson</td>
<td>National Institute on Aging Gerontology Research Center, Baltimore, MD</td>
<td>2003</td>
</tr>
<tr>
<td>Facilitating the Development of PET Diagnostics for Alzheimer's Disease</td>
<td>Ron C. Peck</td>
<td>Neurological Disease Foundation, Burlingame, CA</td>
<td>2005</td>
</tr>
<tr>
<td>New Directions in Neuroprotection Basics: Basic Mechanisms, Molecular Targets and Treatment Strategies</td>
<td>Manfred Windisch</td>
<td>JSW-Research Forschungslabor GmbH, Graz, Austria</td>
<td>2005</td>
</tr>
</tbody>
</table>
Summarized Balance Sheet  As of December 31, 2005

**Assets**
- Cash  $ 1,074,314
- Receivables and Other Assets  197,743

**Total Assets**  $1,272,057

**Liabilities and Net Assets**
- Payables and Accrued Liabilities  110,287
- Net Assets  1,161,770

**Total Liabilities and Net Assets**  $1,272,057

Summarized Operational Information  For The Year Ended December 31, 2005

**Support and Revenues**
- Support - Contributions and Grants  $1,560,538
- Revenues - Investment and Other Income  35,437

**Total Support and Revenues**  1,595,975

**Expenses**
- Program-Related Services  610,148
- Fund Raising and Development  147,052
- Management and General  64,301

**Total expenses**  821,501

**Change in net assets**  774,474

**Net assets, January 1, 2005**  387,296

**Net assets, December 31, 2005**  $ 1,161,770

The accompanying financial information has been derived from the Foundation's 2005 Audited Financial Statements and is presented here in condensed form.

---

Summarized Balance Sheet  As of December 31, 2005

**Assets**
- Cash  $ 3,032,737
- Program-Related Investments  1,398,722
- Property and Equipment  86,709
- Other Assets  72,080

**Total Assets**  $4,590,248

**Liabilities and Net Assets**
- Payables and Accrued Liabilities  9,830
- Net Assets  4,580,418

**Total Liabilities and Net Assets**  $4,590,248

Summarized Operational Information  For The Year Ended December 31, 2005

**Support and Revenues**
- Support - Contributions  $ 3,451,286
- Revenues - Investment Income  57,532

**Total Support and Revenues**  3,508,818

**Expenses**
- Grants  2,066,353
- Program-Related Services  1,825,612
- Management and General / Development  264,385

**Total expenses**  4,156,350

**Change in net assets**  (647,532)

**Net assets, January 1, 2005**  5,227,950

**Net assets, December 31, 2005**  $ 4,580,418

The accompanying financial information has been derived from the Institute's 2005 Audited Financial Statements and is presented here in condensed form.
2005 CONTRIBUTING PARTNERS

We gratefully acknowledge the following partners for their generosity and support. Through their dedication, we are able to advance our mission of accelerating drug discovery research.

Contributions of $1,000,000 and Above

Estée Lauder Family

Contributions of $100,000 and Above

ÉLAN Pharmaceuticals, Inc.
Forest Pharmaceuticals, Inc.

Contributions of $10,000 and Above

Mr. and Mrs. Robert E. Barnhill, Jr.
Mr. and Mrs. John and Lizbeth Cooney
Ms. Nancy Corzine
Dr. and Mrs. Jack and Joy Fishman
The Hazen Polsky Foundation
Ortho-McNeil Neurologics, Inc./Janssen Medical Affairs, LLC
Pfizer, Inc.
The Robert E. & Dorothy Z. Barnhill Family Fund
Mr. and Mrs. Randall Sandler and Lizabeth Furman Sandler

Contributions of $1,000 and Above

Acumen Pharmaceuticals, Inc.
Bloomberg LC
The Claire & Theodore Morse Foundation
The Dalio Family Foundation Inc.
Mr. and Mrs. Robert E. & Dorothy Z. Barnhill Family Fund
Mr. and Mrs. Randal Sandler and Lizabeth Furman Sandler

Contributions of $100 and Above

Ms. Rachel Balsam
Ms. Nancy M. Baycroft
Mr. and Mrs. Boily Thomas
Dr. Fotini M. Dionisopoulos
Mr. and Mrs. Michael and Cynthia Gibbons
Ms. Rosalyn Glick
Mr. and Mrs. Samuel and Lucille Irving
Mr. and Mrs. Robert Gilgen
Mr. and Mrs. Rene and Jay Glass
Mr. and Mrs. Alan and Nancy Kaufman
Mr. and Mrs. Peter Krulwich
Mr. and Mrs. Nancy and Steve Lerner
Mr. and Mrs. Alfred and Bonnie Margulies
Dr. and Mrs. Stephen Deutsch
Mr. and Mrs. Philip and Barbara Falcone
Mr. and Mrs. Robert Gilgen
Mr. and Mrs. Rene and Jay Glass
Ms. Rosalyn Glick
Mr. and Mrs. Samuel and Lucille Irving
Mr. and Mrs. Michael and Mindy Isaacs
Ms. Judith C. Isroff
Ms. Jeanne G. Kaskey
Dr. and Mrs. Steven Lasser
Ms. Bonnie Leisle
The Regal Family
Mr. and Mrs. Kenneth Sherman
Mr. and Mrs. Daniel and Ivy Marwil
Ms. Robin Pearl and Mr. Jonathan Kargman
Mr. Steven Peiser-Bus and Mrs. Libby Peiser
Dr. and Mrs. Stuart Ross

Other Contributing Partners

Partnership Sponsored Programs

Forest Laboratories Inc.
Healthcare Dimensions, Inc.
PacifiCare Health Systems, Inc.
Zoe Finch Totten

The Jon and Susan Rotenstreich Foundation
Martek Biosciences Corporation
Merck & Co.
Neurochem Inc.
The The Herring Finn Foundation
The Jewish Communal Fund
The Douglas and Elizabeth Koor Foundation
Mr. and Mrs. Steven Lasser
Ms. Bonnie Leisle
The Regal Family
Mr. and Mrs. Kenneth Sherman
Dr. and Mrs. Fred and Leslie Sugar
Ms. Amy G. Treitel
Wyeth Pharmaceuticals
The Leonard & Evelyn Lauder Foundation
The Pediatric Dentistry, Ltd. Staff
Fulfilling the Lauder family goal of engaging others to participate in the ADDF mission has been one of the greatest rewards of my lifetime. Throughout 2005, I spoke with hundreds of people and it seemed that one out of every two that I met told me they had a loved one who was suffering from AD or past way from it. At first, they were hesitant in disclosing their experiences, but after hearing about our foundation they spoke more freely and offered suggestions.

With the help of many, we were able to recruit four exceptional people to our new Board of Directors. We also started an Advisory Council with three highly experienced individuals from the healthcare and biotechnology industries. Additionally, we formed a Business Development Committee to assist us with public relations, special events and networking. All of these dedicated people have generously taken the time to act as ADDF ambassadors and rally others to work with us.

As part of our partnership-building and fundraising strategy, we reached out to numerous corporations, foundations and government agencies. They responded so positively that we nearly doubled our anticipated financial goal for 2005, raising $2,455,259.

Concluding my first year at the ADDF, I am convinced that working together is the only way we will be able to cure AD. I am grateful for everyone who has collaborated with us and look forward to building upon our relationships, as well as initiating new ones, in 2006.
Acclerating drug discovery for Alzheimer’s disease through venture philanthropy